Skip to main content
SpringerLink
Log in

Neo-adjuvant chemotherapy for advanced stage endometrial carcinoma: a glimmer of hope in select patients

  • Review
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Purpose of review

The objective of this review is to conduct a critical appraisal of the published literature on the use of neo-adjuvant chemotherapy followed by interval debulking in the treatment of stage IVb endometrial carcinoma patients.

Methods

Narrative review of the pertinent literature on the application of neo-adjuvant chemotherapy and interval surgery in the treatment of advanced stage endometrial cancers.

Results

Advanced stage endometrial carcinoma patients are treated by aggressive cytoreduction followed by adjuvant chemotherapy or by chemotherapy alone. The prognosis of patients that cannot undergo surgery is extremely poor. Preoperative reduction of tumor burden by chemotherapy can facilitate surgery in patients previously considered to have an unresectable disease, identify patients with chemo-sensitive tumors that are more likely to benefit from surgery, and enable a less aggressive surgery thus reducing morbidity. However, only 106 cases of neo-adjuvant chemotherapy were documented in the last two decades, majority (76) were described in retrospective case reports and case series. The available data may indicate feasibility of neo-adjuvant treatment in select patients. Compared to patients that had primary surgery, neo-adjuvant setting was associated with improved or equivalent survival and maximal debulking rates and reduced postoperative morbidity.

Conclusions

Until further progress is reached, consideration can be given to recommending neo-adjuvant chemotherapy followed by interval debulking to patients with poor performance status or those patients who the surgeon believes would have suboptimal debulking if surgery was attempted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9–29. doi:10.3322/caac.21208

    Article  PubMed  Google Scholar 

  2. SEER Cancer Statistics Factsheets: Endometrial Cancer 2014. National Cancer Institute Bethesda, MD. http://www.seercancergov/statfacts/html/corphtml. Accessed 10 Jan 2015

  3. Schorge JO, Clark RM, Lee SI, Penson RT (2014) Primary debulking surgery for advanced ovarian cancer: are you a believer or a dissenter? Gynecol Oncol. doi:10.1016/j.ygyno.2014.10.007

    Google Scholar 

  4. Eto T, Saito T, Shimokawa M, Hatae M, Takeshima N, Kobayashi H, Kasamatsu T, Yoshikawa H, Kamura T, Konishi I (2013) Status of treatment for the overall population of patients with stage IVb endometrial cancer, and evaluation of the role of preoperative chemotherapy: a retrospective multi-institutional study of 426 patients in Japan. Gynecol Oncol 131(3):574–580. doi:10.1016/j.ygyno.2013.08.036

    Article  PubMed  Google Scholar 

  5. Dowdy SC (2014) Improving oncologic outcomes for women with endometrial cancer: realigning our sights. Gynecol Oncol 133(2):370–374. doi:10.1016/j.ygyno.2014.02.019

    Article  PubMed  PubMed Central  Google Scholar 

  6. NCCN (2015) NCCN Clinical Practice Guidelines in Oncology, Uterine Neoplasms version 2.2015. http://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf. Accessed 13 Mar 2015

  7. Vandenput I, Van Calster B, Capoen A, Leunen K, Berteloot P, Neven P, Moerman P, Vergote I, Amant F (2009) Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment? Br J Cancer 101(2):244–249. doi:10.1038/sj.bjc.6605157

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  8. Barlin JN, Puri I, Bristow RE (2010) Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. Gynecol Oncol 118(1):14–18. doi:10.1016/j.ygyno.2010.04.005

    Article  PubMed  Google Scholar 

  9. Shih KK, Yun E, Gardner GJ, Barakat RR, Chi DS, Leitao MM Jr (2011) Surgical cytoreduction in stage IV endometrioid endometrial carcinoma. Gynecol Oncol 122(3):608–611. doi:10.1016/j.ygyno.2011.05.020

    Article  PubMed  CAS  Google Scholar 

  10. Galaal K, Al Moundhri M, Bryant A, Lopes AD, Lawrie TA (2014) Adjuvant chemotherapy for advanced endometrial cancer. The Cochrane database of systematic reviews 5:Cd010681. doi:10.1002/14651858.CD010681.pub2

  11. Vale CL, Tierney J, Bull SJ, Symonds PR (2012) Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. The Cochrane database of systematic reviews 8:Cd003915. doi:10.1002/14651858.CD003915.pub4

  12. van Wijk FH, Huikeshoven FJ, Abdulkadir L, Ewing PC, Burger CW (2006) Stage III and IV endometrial cancer: a 20-year review of patients. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 16(4):1648–1655. doi:10.1111/j.1525-1438.2006.00639.x

    Article  Google Scholar 

  13. Resnik E, Taxy JB (1996) Neoadjuvant chemotherapy in uterine papillary serous carcinoma. Gynecol Oncol 62(1):123–127. doi:10.1006/gyno.1996.0201

    Article  PubMed  CAS  Google Scholar 

  14. Le TD, Yamada SD, Rutgers JL, DiSaia PJ (1999) Complete response of a stage IV uterine papillary serous carcinoma to neoadjuvant chemotherapy with Taxol and carboplatin. Gynecol Oncol 73(3):461–463. doi:10.1006/gyno.1999.5361

    Article  PubMed  CAS  Google Scholar 

  15. Price FV, Amin RM, Sumkin J (1999) Complete clinical responses to neoadjuvant chemotherapy for uterine serous carcinoma. Gynecol Oncol 73(1):140–144. doi:10.1006/gyno.1998.5303

    Article  PubMed  CAS  Google Scholar 

  16. Despierre E, Moerman P, Vergote I, Amant F (2006) Is there a role for neoadjuvant chemotherapy in the treatment of stage IV serous endometrial carcinoma? Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 16(Suppl 1):273–277. doi:10.1111/j.1525-1438.2006.00416.x

    Article  Google Scholar 

  17. Amant F, Vergote I (2010) What is the role of neoadjuvant chemotherapy in advanced endometrial cancer? Gynecol Oncol 119(3):601. doi:10.1016/j.ygyno.2010.08.009 (author reply 601–602)

    Article  PubMed  Google Scholar 

  18. Barlin JN, Bristow RE (2010) Response to:“What is the role of neoadjuvant chemotherapy in advanced endometrial cancer?”. Gynecol Oncol 119(3):601–602

    Article  Google Scholar 

  19. Wilkinson-Ryan I, Frolova AI, Liu J, Stewart Massad L, Thaker PH, Powell MA, Mutch DG, Hagemann AR (2015) Neoadjuvant chemotherapy versus primary cytoreductive surgery for stage IV uterine serous carcinoma. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 25(1):63–68. doi:10.1097/igc.0000000000000321

    Article  Google Scholar 

  20. Thigpen JT, Brady MF, Alvarez RD, Adelson MD, Homesley HD, Manetta A, Soper JT, Given FT (1999) Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the gynecologic oncology group. J Clin Oncol Off J Am Soc Clin Oncol 17(6):1736–1744

    CAS  Google Scholar 

  21. Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, Thigpen JT, Benda JA (2006) Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol Off J Am Soc Clin Oncol 24(1):36–44. doi:10.1200/jco.2004.00.7617

    Article  CAS  Google Scholar 

  22. Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, Kline R, Burger RA, Goodman A, Burks RT (2004) Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol Off J Am Soc Clin Oncol 22(11):2159–2166. doi:10.1200/jco.2004.07.184

    Article  CAS  Google Scholar 

  23. Chambers JT, Chambers SK, Voynick IM, Schwartz PE (1990) Neoadjuvant chemotherapy in stage X ovarian carcinoma. Gynecol Oncol 37(3):327–331

    Article  PubMed  CAS  Google Scholar 

  24. Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, Luesley D, Perren T, Bannoo S, Mascarenhas M, Dobbs S, Essapen S, Twigg J, Herod J, McCluggage G, Parmar M, Swart AM (2015) Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. doi:10.1016/s0140-6736(14)62223-6

    Google Scholar 

  25. Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New Engl J Med 363(10):943–953. doi:10.1056/NEJMoa0908806

    Article  PubMed  CAS  Google Scholar 

  26. Landrum LM, Moore KN, Myers TK, Lanneau GS Jr, McMeekin DS, Walker JL, Gold MA (2009) Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis. Gynecol Oncol 112(2):337–341. doi:10.1016/j.ygyno.2008.10.009

    Article  PubMed  Google Scholar 

  27. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497(7447):67–73. doi:10.1038/nature12113

    Article  PubMed  Google Scholar 

  28. Sagae S, Susumu N, Viswanathan AN, Aoki D, Backes FJ, Provencher DM, Vaughan M, Creutzberg CL, Kurzeder C, Kristensen G, Lee C, Kurtz JE, Glasspool RM, Small W Jr (2014) Gynecologic cancer intergroup (GCIG) consensus review for uterine serous carcinoma. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 24(9 Suppl 3):S83–S89. doi:10.1097/igc.0000000000000264

    Article  Google Scholar 

  29. Deleon MC, Ammakkanavar NR, Matei D (2014) Adjuvant therapy for endometrial cancer. J Gynecol Oncol 25(2):136–147. doi:10.3802/jgo.2014.25.2.136

    Article  PubMed  PubMed Central  Google Scholar 

  30. Ayeni TA, Bakkum-Gamez JN, Mariani A, McGree ME, Weaver AL, Haddock MG, Keeney GL, Long HJ 3rd, Dowdy SC, Podratz KC (2013) Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas. Gynecol Oncol 129(3):478–485. doi:10.1016/j.ygyno.2013.03.011

    Article  PubMed  Google Scholar 

  31. Goldfinger M, Diaz I, Muggia F (2014) Systemic treatment of endometrial cancer: what is doxorubicin’s role? J Clin Oncol Off J Am Soc Clin Oncol 32(20):2181–2182. doi:10.1200/jco.2014.55.7454

    Article  Google Scholar 

  32. Filiaci V, Fleming G, Mannel R, Cohn D, Matsumoto T, Tewari K, DiSilvestro P, Pearl M, Zaino R (2012) Late-breaking abstract 1: randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol 125(3):771. doi:10.1016/j.ygyno.2012.03.034

    Google Scholar 

  33. Simpkins F, Drake R, Escobar PF, Nutter B, Rasool N, Rose PG (2015) A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA). Gynecol Oncol 136(2):240–245. doi:10.1016/j.ygyno.2014.12.004

    Article  PubMed  CAS  Google Scholar 

  34. Rutten MJ, van de Vrie R, Bruining A, Spijkerboer AM, Mol BW, Kenter GG, Buist MR (2015) predicting surgical outcome in patients with international federation of gynecology and obstetrics stage III or IV ovarian cancer using computed tomography: a systematic review of prediction models. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 25(3):407–415. doi:10.1097/igc.0000000000000368

    Article  Google Scholar 

  35. Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Mironov S, Iyer RB, Zhou Q, Iasonos A, Paul H, Hosaka M, Aghajanian CA, Leitao MM Jr, Gardner GJ, Abu-Rustum NR, Sonoda Y, Levine DA, Hricak H, Chi DS (2014) A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecol Oncol 134(3):455–461. doi:10.1016/j.ygyno.2014.07.002

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  36. Rutten MJ, Leeflang MM, Kenter GG, Mol BW, Buist M (2014) Laparoscopy for diagnosing resectability of disease in patients with advanced ovarian cancer. The Cochrane database of systematic reviews 2:Cd009786. doi:10.1002/14651858.CD009786.pub2

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, P.O. Box 151, 84101, Beer-Sheva, Israel

    Alex Rabinovich

Authors
  1. Alex Rabinovich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alex Rabinovich.

Ethics declarations

Conflict of interest

Author declares no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rabinovich, A. Neo-adjuvant chemotherapy for advanced stage endometrial carcinoma: a glimmer of hope in select patients. Arch Gynecol Obstet 293, 47–53 (2016). https://doi.org/10.1007/s00404-015-3841-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-015-3841-8

Keywords

Search

Navigation